HOME >> BIOLOGY >> NEWS
Duke Researchers Find Second Gene Linked To Blood Vessel Disorder

DURHAM, N.C. -- Duke University Medical Center researchers have linked a second gene to a rare bleeding disorder -- a discovery that offers insight into how blood vessels form and heal in response to injury.

The finding links a previously identified human gene called activin receptor like kinase 1 (ALK1) to the disease hereditary hemorrhagic telangiectasia (HHT), a bleeding disorder that strikes 1 in 40,000 people. Geneticist Doug Marchuk, postdoctoral researcher David Johnson, the study's lead author, and colleagues from Duke and from six other research institutions reported the finding in the June issue of Nature Genetics. The study was funded by the National Institutes of Health, the American Heart Association, and the Baxter Foundation.

HHT, also known as Osler-Weber-Rendu disease, causes tiny veins to fuse into one large mass that can easily be ruptured, causing recurrent bleeding episodes in affected people. In some people, the disease is only a cosmetic problem with tiny red blotches forming on skin or recurring nose bleeds. Others suffer migraine headaches or lesions in the lung or brain that can lead to fatal strokes or aneurysms.

"By studying these genes for rare disorders, we are hoping to open a window into how the body's vascular system operates," Marchuk, assistant professor of genetics, said in an interview. "People often ask, why study genes for a rare disease? First, the disease may be rare, but the genes aren't rare. Everyone has these genes, and we would like to know how they operate normally so we can understand what can go wrong. Second, when it's your family with the disease, it is very important. We would like to be able to offer some hope to these families."

The protein encoded by the ALK1 gene appears to be made almost exclusively in the cells that line blood vessels. While researchers aren't sure of its function, it appears to interact with the potent growth factor, transforming growth factor
'"/>

Contact: Karyn Hede George
georg016@mc.duke.edu
919-660-1301
Duke University
31-May-1996


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Duke Researchers Find Second Gene Linked Blood Vessel Disorder

(Date:5/21/2013)... MA -- Over the past few decades, scientists have ... angioplasty balloons and metallic stents. While generally effective, each ... side effects. , A new study from MIT analyzes ... the benefits of angioplasty balloons and drug-releasing stents, but ... balloon is inflated in the artery for only a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
(Date:5/20/2013)... (NSF) planning grant will help establish the Center for ... the University of Illinois at Urbana-Champaign and Worcester Polytechnic ... devoted to research in drying moist, porous materials such ... products; chemical products; textiles; and biopharmaceuticals," said Hao Feng, ... human nutrition and the Illinois site director. , According ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
(Date:5/21/2013)... MN (PRWEB) May 21, 2013 The ... show display solution for sales and marketing teams looking for ... describes the kit as “everything you’ll need to put ... Fabric Display Kit comes with a number of displays and ... trade booth 20 feet by 20 feet in size. These ...
(Date:5/20/2013)... May 21, 2013 Grace Century ... in “game-changing” life science and health related private equity ... to its International Project Team. Dergham's expertise in finance ... multi-cultural depth to Grace Century as it continues to ... , Ms. Dergham holds both an under graduate degree ...
(Date:5/20/2013)... , May 20, 2013 Today, at the ... Francisco , James McGough , ... at the Semel Institute for Neuroscience and Human Behavior ... Medicine at the University of California Los Angeles (UCLA), ... and Adolescent Psychopharmacology and ADHD at UCLA, presented the ...
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and Clinigene ... for developers of biosimilars at the 2013 AAPS/ ... San Diego Hotel and Marina , ... have the opportunity to speak with company representatives at ... That Cross" on May 21 from 1-2 p.m. in ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2
Cached News: